ChiCTR2200062619
Untitled Trial
A prospective study on the efficacy of tyrosine Kinase Inhibitor combined with chemotherapy in the core binding factor acute myeloid leukemia patients with KIT mutation
Peking University People's Hospital·Phase 1·Chinese Clinical Trial RegistryNot yet recruiting
View on Chinese Clinical Trial Registry →Study focus
- Disease/Condition
- Leukemia
Sponsor & location
- Primary sponsor
- Peking University People's Hospital
- Funder
- National Natural Science Foundation of China
- Location
- China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- N/A
- End date
- Aug 01, 2024
ICD-10 classifications
Leukaemia, unspecifiedMyeloid leukaemiaMyeloid leukaemia, unspecifiedOther myeloid leukaemiaMonocytic leukaemia, unspecified
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2200062619
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2200062619 through Pure Global AI's free database. This Phase 1 trial is sponsored by Peking University People's Hospital and is currently Not yet recruiting. The study focuses on Leukemia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.